Antibodies directed towards neuraminidase restrict influenza virus replication in primary human bronchial epithelial cells.
Animals
Antibodies, Monoclonal
/ immunology
Antibodies, Viral
/ immunology
Cell Line
Epithelial Cells
/ immunology
Humans
Influenza A Virus, H1N1 Subtype
/ physiology
Influenza, Human
/ immunology
Mice
Neuraminidase
/ immunology
Respiratory Mucosa
/ immunology
Viral Proteins
/ immunology
Virus Replication
/ immunology
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
14
10
2021
accepted:
06
01
2022
entrez:
31
1
2022
pubmed:
1
2
2022
medline:
22
2
2022
Statut:
epublish
Résumé
Influenza neuraminidase (NA) is implicated in various aspects of the virus replication cycle and therefore is an attractive target for vaccination and antiviral strategies. Here we investigated the potential for NA-specific antibodies to interfere with A(H1N1)pdm09 replication in primary human airway epithelial (HAE) cells. Mouse polyclonal anti-NA sera and a monoclonal antibody could block initial viral entry into HAE cells as well as egress from the cell surface. NA-specific polyclonal serum also reduced virus replication across multiple rounds of infection. Restriction of virus entry correlated with the ability of the serum or monoclonal antibody to mediate neuraminidase inhibition (NI). Finally, human sera with NI activity against the N1 of A(H1N1)pdm09 could decrease H6N1 virus infection of HAE cells, highlighting the potential contribution of anti-NA antibodies in the control of influenza virus infection in humans.
Identifiants
pubmed: 35100294
doi: 10.1371/journal.pone.0262873
pii: PONE-D-21-32986
pmc: PMC8803191
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Viral
0
Viral Proteins
0
NA protein, influenza A virus
EC 3.2.1.18
Neuraminidase
EC 3.2.1.18
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0262873Déclaration de conflit d'intérêts
This manuscript was internally reviewed and approved by SP for publication without major modifications on its content. X.S. received research support from Sanofi Pasteur for this work. H.K. and T.U.V. report to have stock options from Sanofi-Pasteur. T.U.V. is employed by SP. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
Microbes Infect. 2006 Apr;8(5):1287-93
pubmed: 16682242
J Virol. 2012 Jun;86(11):6179-88
pubmed: 22491456
J Histochem Cytochem. 2015 May;63(5):312-28
pubmed: 25604814
Nat Microbiol. 2017 Oct;2(10):1415-1424
pubmed: 28827718
Sci Rep. 2015 Mar 16;5:9163
pubmed: 25772381
Nat Microbiol. 2019 Jun;4(6):1024-1034
pubmed: 30886361
J Vis Exp. 2016 Sep 06;(115):
pubmed: 27684188
PLoS One. 2013;8(3):e59623
pubmed: 23544079
Nat Microbiol. 2019 Dec;4(12):2216-2225
pubmed: 31406333
PLoS Pathog. 2018 Aug 13;14(8):e1007233
pubmed: 30102740
Nat Commun. 2015 Feb 10;6:6114
pubmed: 25668439
Science. 2019 Oct 25;366(6464):499-504
pubmed: 31649200
mBio. 2017 Mar 21;8(2):
pubmed: 28325769
Vaccine. 1996 Apr;14(6):561-9
pubmed: 8782356
Science. 2009 Apr 10;324(5924):246-51
pubmed: 19251591
Antiviral Res. 2016 Nov;135:48-55
pubmed: 27713074
Cell Host Microbe. 2019 Dec 11;26(6):715-728.e8
pubmed: 31757769
J Infect Dis. 2015 Dec 15;212(12):1914-22
pubmed: 26014800
mBio. 2018 Jan 23;9(1):
pubmed: 29362240
Hum Vaccin Immunother. 2018;14(8):1840-1847
pubmed: 29641358
NPJ Vaccines. 2020 Jan 10;5(1):3
pubmed: 31934357
Virology. 1974 Oct;61(2):397-410
pubmed: 4472498
J Virol. 2006 Feb;80(4):2013-8
pubmed: 16439557
Virol J. 2013 Nov 22;10:321
pubmed: 24261589
J Virol. 1969 Oct;4(4):528-34
pubmed: 5823234
J Clin Invest. 2016 Feb;126(2):605-10
pubmed: 26731473
J Virol. 2013 Aug;87(16):9290-300
pubmed: 23785204
Vaccine. 2010 Aug 16;28(36):5774-84
pubmed: 20621113
Cell. 2018 Apr 5;173(2):417-429.e10
pubmed: 29625056
Am J Respir Cell Mol Biol. 1996 Jan;14(1):104-12
pubmed: 8534481
J Virol. 2018 Jan 30;92(4):
pubmed: 29167342
Nat Immunol. 2014 Mar;15(3):248-57
pubmed: 24441789
Sci Rep. 2017 Mar 27;7:45043
pubmed: 28344335
mBio. 2016 Apr 19;7(2):e00417-16
pubmed: 27094330
J Virol. 1969 Jul;4(1):58-66
pubmed: 5817556
Sci Rep. 2016 Apr 13;6:24402
pubmed: 27072615
Clin Vaccine Immunol. 2016 Jan 13;23(3):228-35
pubmed: 26762363
J Virol. 2004 Nov;78(22):12665-7
pubmed: 15507653
mBio. 2019 Oct 22;10(5):
pubmed: 31641082
PLoS One. 2009 Dec 30;4(12):e8495
pubmed: 20041119
mBio. 2015 Mar 10;6(2):e02556
pubmed: 25759506
PLoS Pathog. 2020 Jun 29;16(6):e1008411
pubmed: 32598381
J Mol Biol. 1991 Sep 20;221(2):473-86
pubmed: 1920428